title: Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer.
abstract: BACKGROUND
  Quality of life (QoL) has become a major outcome in the treatment of patients with cancer. This study is aimed at examining the impact of chemotherapy-induced nausea and vomiting on QoL of patients with gynecologic cancer in Indonesia.
  
  
  METHODS
  Chemotherapy-naive patients with gynecologic cancer, who were treated with cisplatin at a dosage 50 mg/m or higher as monotherapy or as part of combination chemotherapy regimens, were recruited in the Oncology Department, Dr. Sardjito Hospital, Yogyakarta, Indonesia. Quality of life was assessed by using the Indonesian version of the European Organization for Research and Treatment for Cancer of Quality of Life Questionnaire and Short Form-36, administered immediately before and on day 5 after chemotherapy administration. Patients used a daily diary to record nausea and vomiting during 5 days after chemotherapy.
  
  
  RESULTS
  Most (74.9%) of the 179 patients experienced delayed emesis during the 5 days after chemotherapy despite prophylactic use of antiemetics. The delayed nausea and emesis caused significant negative impact on patients' QoL. Nausea in the delayed phase caused negative effects on patients' QoL.
  
  
  CONCLUSIONS
  Patients reported a negative impact on the QoL of delayed emesis after chemotherapy. Poor prophylaxis of patients' nausea and vomiting after chemotherapy interferes with patients' QoL. Medical and behavioral interventions may help to alleviate the negative consequences of chemotherapeutic treatment in patients with gynecologic cancers treated with suboptimal antiemetics.
authors.affiliation: Pharmacy Faculty, Ahmad Dahlan University, Yogyakarta, Indonesia. D.A.Perwitasari@lumc.nl
authors.forename: Dyah Aryani
authors.initials: DA
authors.lastname: Perwitasari
authors.forename: Jarir
authors.initials: J
authors.lastname: Atthobari
authors.forename: Mustofa
authors.initials: M
authors.lastname: Mustofa
authors.forename: Iwan
authors.initials: I
authors.lastname: Dwiprahasto
authors.forename: Mohammad
authors.initials: M
authors.lastname: Hakimi
authors.forename: Hans
authors.initials: H
authors.lastname: Gelderblom
authors.forename: Hein
authors.initials: H
authors.lastname: Putter
authors.forename: Johan W R
authors.initials: JW
authors.lastname: Nortier
authors.forename: Henk-Jan
authors.initials: HJ
authors.lastname: Guchelaar
authors.forename: Ad A
authors.initials: AA
authors.lastname: Kaptein
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D007214:Indonesia; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D002945:Cisplatin